SCHEMBL14236172

SCHEMBL14236172

O=C(O)c1cc(Br)c2c(c1Br)CCCC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ GFER P55789 1/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ AKR1C4 P17516 1/20 0.37
▸ AKR1C3 P42330 1/20 0.37
▸ AKR1C2 P52895 1/20 0.37
▸ AKR1C1 Q04828 1/20 0.37
▸ AMPD1 P23109 1/20 0.37
▸ AMPD3 Q01432 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ HSD17B10 Q99714 3/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ PLA2G1B P04054 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ ATG4B Q9Y4P1 1/20 0.36
▸ PRNP P04156 1/20 0.35
▸ PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14128389 0.96 SMN1; SMN2 (0.40) SMN1; SMN2GFERMEN1KMT2AAKR1C4
SCHEMBL29723114 0.96 SMN1; SMN2 (0.40) SMN1; SMN2GFERMEN1KMT2AAKR1C4
SCHEMBL14236372 0.79 NPC1 (0.32) MEN1KMT2AALDH1A1ALOX15
SCHEMBL20643007 0.78 SMN1; SMN2 (0.38) SMN1; SMN2MEN1KMT2AAKR1C4AKR1C3
SCHEMBL19330645 0.78 KDM4E (0.42) SMN1; SMN2GFERMEN1KMT2AAKR1C4
SCHEMBL20558628 0.74 GAA (0.42) SMN1; SMN2MEN1KMT2AAKR1C4AKR1C3
SCHEMBL3551316 0.73 MEN1 (0.41) GFERMEN1KMT2AALDH1A1HSD17B10
SCHEMBL14235747 0.71 MAPT (0.45) SMN1; SMN2MEN1KMT2AALDH1A1HPGD
SCHEMBL14128277 0.71 SLC6A3 (0.39) MEN1KMT2AALDH1A1TDP1
SCHEMBL19124079 0.70 GAA (0.42) SMN1; SMN2MEN1KMT2AAKR1C4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 — — EP disclosed
EP-2714032-B1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORP (KR) 2019-01-16 — — EP disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-9371303-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2016-06-21 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2015-06-04 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-9034921-B2 Diphenylmethane derivatives as SGLT2 inhibitors GREEN CROSS CORPORATION (KR) 2015-05-19 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2014-03-27 — — US disclosed
WO-2012165914-A2 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS GREEN CROSS CORPORATION (KR) 2012-12-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088079-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 SMN1; SMN2 4345/4885GFER 2678/4885MEN1 4040/4885
US-20150152075-A1 NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS SLC5A2, SLC5A1, SLC2A8 SMN1; SMN2 4006/4885GFER 2749/4885MEN1 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback